Physician profile
Michael J Lacqua
NPI 1992753883
$864,527.04
in general payments reported to CMS, 2019-2025
19 companies · $59K in 2025
The $59K reported for 2025 was more than what 99% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $98K · 2021: $68.11 · 2022: $118K · 2023: $483K · 2024: $95K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $345K · Consulting Fee: $123K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $42K · Travel and Lodging: $28K · Food and Beverage: $4,851 · Education: $1,600 · Honoraria: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $345,427.51 |
| Consulting Fee | $122,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,999.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $42,100.00 |
| Travel and Lodging | $27,717.93 |
| Food and Beverage | $4,850.84 |
| Education | $1,600.00 |
| Honoraria | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $807,983.28 | 2019-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Convatec INC. | $54,363.54 | 2022-2025 | |
| Triad Life Sciences INC. | $1,173.47 | 2022 | |
| Smith+Nephew, INC. | $251.17 | 2019-2025 | Collagenase Santyl |
| Tela Bio, INC. | $168.04 | 2024-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Organogenesis INC. | $124.37 | 2019 | |
| Axogen | $95.92 | 2019-2025 | Avance Nerve Graft |
| Solventum Corporation | $60.02 | 2024-2025 | V.A.C. Veraflo, V.A.C.Ulta, V.A.C. Veraflo Cleanse Choice |
| Vertex Pharmaceuticals Incorporated | $46.46 | 2025 | |
| Mentor Worldwide LLC | $43.08 | 2019-2022 | |
| Abbvie INC. | $35.73 | 2022 | |
| Depuy Synthes Sales INC. | $35.70 | 2020 | |
| Integra Lifesciences Corporation | $31.87 | 2019-2020 | |
| Stryker Corporation | $25.88 | 2020 | |
| Melinta Therapeutics, LLC | $24.40 | 2025 | Orbactiv, Kimyrsa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $18.57 | 2020 | |
| Paratek Pharmaceuticals, INC. | $17.59 | 2023 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $14.17 | 2022 | |
| Allergan, INC. | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$749,529.34 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lacqua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.